Weitai Medical, a Hangzhou based maker of wearable glucose sensors for diabetes patients, saw overseas revenue hit ¥343 million in 2025, exceeding its China business for the first time.
For the first time, Weitai Medical's foreign business was bigger than its home one. The Hangzhou-based maker of continuous glucose monitors, the small wearable sensors that track blood sugar around the clock for people with diabetes, posted ¥343 million in overseas revenue in 2025, up 227.2% year over year, and crossed the ¥318 million it earned in China, according to the company's annual results filed with the Hong Kong Stock Exchange. Total revenue hit ¥661 million, up 91.2%, and the company recorded its first annual net profit, ¥40.15 million, after years of losses.
The split between products matters more than the headline growth rate. Continuous glucose monitors, known as CGMs, made up 68.3% of revenue in 2025, up from 52.2% in 2024, per the annual report, generating ¥452 million. The remainder sits in patch insulin pumps, a smaller but growing category. Weitai's pump integrates the motor, reservoir, drive, and infusion needle into a 23-gram wearable that adheres to the skin, per the company's annual filing. That dual capability, one of the few Chinese companies with both a CGM and a pump on the same platform, is the foundation the company is now building an artificial pancreas product on.
The mechanism behind the overseas surge is a regulatory-first sequencing strategy that most Chinese medical device peers have not run. Weitai won European CE certification, the safety mark required to sell medical devices in the European Union, for its insulin pump in 2017, several years before most domestic rivals had filed, and CE certification for its CGM in 2020, according to its HKEX filing. With that mark in hand, the company entered Italy, Poland, and Romania first, using contract-research-supported clinical studies to build the country-specific evidence that European reimbursement and insurance systems require, according to an executive interview reported by 36Kr. Only after that base was in place did it expand into Germany, the Netherlands, and the United Kingdom, where incumbents Abbott and Dexcom are deeply entrenched in hospital and payor relationships.
Shi Yonghui, Weitai's executive director and chief strategy officer, told 36Kr that the company learned early that European markets are not won on price. The first task is to satisfy each country's clinical evidence and reimbursement requirements separately, then build a local sales footprint. The result is a hybrid channel strategy: in reimbursement-driven hospital and payor channels, Weitai co-brands with local partners, and the AiDEX name may not be visible to the prescribing doctor; on consumer channels like Amazon, the same products sell under Weitai's own brand. The AiDEX G7 CGM has been on the market in both China and overseas since 2021, per company materials at the time of launch.
The structural advantage is the time it takes to copy. A Chinese rival entering Europe today would need to build clinical-data relationships, country-by-country reimbursement dossiers, and a sales presence in markets where incumbents already hold hospital and payor contracts. Analysts at Huachuang Securities estimated in an April 2026 note that the path to a mature European presence takes three to five years. Weitai started that clock in 2017. Earlier financial coverage, including a preliminary results note on Eastmoney and the Huasheng Tong financial data page for ticker 02235.HK, had already flagged the trend, but the annual filing made it official.
The story has real limits. Some of the demand is a lifestyle wave, a Chinese trend known as '控糖' (blood-sugar control) in which consumers use CGMs to manage glucose for general wellness rather than to treat diabetes. In mature overseas markets, roughly 10% of CGM users are not diabetic, according to industry research cited by 36Kr. That is a tailwind, but it is a vulnerable one: a cooling consumer appetite for wellness tracking would shrink the addressable pool.
Patent exposure is the other constraint. Abbott and Dexcom have pressed infringement claims against Chinese CGM makers, including Weitai, in European and U.S. courts, according to trade-press coverage of the CGM competition. The lawsuits are an ongoing operating cost, not a settled past, and the headline 227% growth still has to clear that drag.
The China side of the picture is also shifting. Domestic online CGM sales hit roughly ¥1.54 billion in 2025, up 45.8%, per industry data cited by 36Kr. The category was foreign-brand dominated before 2020; the first domestic CGM approval came in 2021, and the market has since fragmented. China's overall medical device exports reached $7.09 billion in the first four months of 2026, up 12.4% year on year, per trade data cited in the 36Kr piece. Weitai is one of the more visible names in that export wave, but it is not the only one.
What to watch next is a product the company has not yet shipped. Weitai has guided that an artificial pancreas system, combining its patch pump, CGM, and a proprietary algorithm for automated insulin delivery, will launch in China by the end of 2026, according to the company's annual results. That target is a forward-looking plan, not a confirmed ship date, and the broader test is whether Weitai can carry the European sequencing model into a domestic market that is itself becoming more crowded.
For now, the 227% number is the headline. The mechanism behind it is the part that is harder to copy.